AI could help match pancreatic cancer patients to the right chemo

NCT ID NCT06320717

Recruiting now Knowledge-focused Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study collects blood and tumor samples from 100 people with pancreatic cancer who are about to receive standard chemotherapy before surgery. Researchers will use an artificial intelligence algorithm to analyze the tumor tissue and look for biomarkers that predict which treatment works best. The goal is to develop a tool that helps doctors personalize chemotherapy choices for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a test that helps doctors choose the most effective chemotherapy for each pancreatic cancer patient before surgery.
What could go wrong: This is an early observational study, not a treatment trial. The AI biomarker may not prove accurate enough to change clinical practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Good Samaritan University Hospital
RECRUITING

West Islip, New York, 11795, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.